Inify Laboratories Secures Major Funding, Fuels AI-Driven Diagnostics Expansion
December 20, 2025, 3:38 am
Inify Laboratories secured NOK 92 million in a private placement. A subsequent repair issue targets NOK 8 million. This significant capital influx bolsters the company’s financial stability. It directly funds critical UK expansion projects. Inify stands as a leader in AI-driven diagnostics. The firm excels in histopathology, focusing on prostate cancer and gastroenterology. Its advanced digital workflow optimizes patient pathways. This strategic financial maneuver underlines Inify’s ambitious growth plans. It solidifies its innovative stance in the medical diagnostics market, driving future developments and expanding its international footprint.
Inify Laboratories announced a significant capital raise. The company secured approximately NOK 92 million. This came from a private placement of new shares. The placement closed on December 16, 2025. It targets existing shareholders. These investors held over 1,000,000 shares. The offer price was NOK 3.50 per share.
Preliminary results confirm success. The company received subscriptions for 25,759,315 shares. Any unallotted shares go to guarantors. Monsun AS and Auris AS back the placement. Final results are pending. An announcement is expected on December 19, 2025. This move strengthens Inify's financial position. It ensures operational persistence.
The net proceeds serve a clear purpose. Funds address delays in a fit-out project. They cover larger-than-expected investments. These relate to Inify's UK establishment. The UK market is a key growth area. This funding ensures smooth expansion. It secures future development.
Share settlement follows a timeline. Payment for private placement shares is due around March 25, 2026. New shares will deliver by March 30, 2026. This relies on registration. The Swedish Companies Registration Office must process the capital increase. Euroclear Sweden and Euronext Securities Oslo must also register the shares. Shares will trade on Euronext Growth Oslo. This occurs once all registrations complete.
A repair issue also features in the funding strategy. This issue targets approximately NOK 8 million. It offers new shares. This provides a chance for other investors. It is directed pro-rata. Shareholders not in the private placement can participate. This includes those holding under 1,000,000 shares. The offer price matches the private placement. It is NOK 3.50 per share.
Key dates define the repair issue. Terms were announced on December 17, 2025. The last day to trade with rights was December 16, 2025. The ex-date was December 17, 2025. The record date is December 18, 2025. Shareholders registered in Euronext Securities Oslo (VPS) receive subscription rights. These rights are non-tradable. Euroclear-registered shareholders receive application forms.
The repair issue application period opens in January 2026. It is expected from January 12 to January 26. Final approval for the shares is anticipated around January 27, 2026. A maximum of 2,304,563 new shares are available. This ensures broad shareholder participation. It underscores Inify's commitment to investor fairness.
Inify Laboratories operates at the forefront of diagnostics. The company specializes in histopathology. Its services streamline patient pathways. This includes prostate cancer and gastroenterology diagnostics. Inify provides an integrated service. It spans from sample handling to final diagnosis. Their laboratory system is highly scalable. It handles large patient volumes. It also allows replication in new locations.
Quality is paramount at Inify. Response times are optimized at every step. This covers logistics, tissue preparation, and diagnosis. A fully digital workflow drives this efficiency. It is standardized. It is AI-assisted. This technology sets Inify apart.
Diagnosis remains a human endeavor. Pathologists perform the final diagnosis. Inify’s proprietary AI supports them. This AI boasts world-leading precision. Clinical evaluations confirm its accuracy. The entire workflow operates on a tailor-made system. This system allows for future expansion. It can include additional diagnostic areas.
Inify Laboratories is an international group. Its headquarters are in Stockholm, Sweden. Local laboratories operate in Sweden and the UK. The company’s share trades on Euronext Growth Oslo. Its ticker is INIFY.
The company engaged expert advisors for these transactions. SB1 Markets AS served as financial advisor. Schjødt law firm acted as legal counsel. Their expertise guided Inify through the complex capital raises.
This dual fundraising strategy is crucial. It supports Inify's ambitious growth. It funds essential infrastructure. It expands market reach. The focus on AI-driven diagnostics positions Inify for leadership. It transforms traditional pathology. The company is poised for significant future advancements. It continues to innovate patient care. This ensures long-term financial health. It secures its competitive edge.
The investment reflects market confidence. Investors see value in Inify’s model. Digital pathology is the future. AI integration speeds diagnoses. It boosts accuracy. Inify delivers this future today. Their commitment to innovation remains strong. Their financial foundation is now firmer. This enables continued expansion and technological progress. Inify leads the charge in modern medical diagnostics.
Inify Laboratories announced a significant capital raise. The company secured approximately NOK 92 million. This came from a private placement of new shares. The placement closed on December 16, 2025. It targets existing shareholders. These investors held over 1,000,000 shares. The offer price was NOK 3.50 per share.
Preliminary results confirm success. The company received subscriptions for 25,759,315 shares. Any unallotted shares go to guarantors. Monsun AS and Auris AS back the placement. Final results are pending. An announcement is expected on December 19, 2025. This move strengthens Inify's financial position. It ensures operational persistence.
The net proceeds serve a clear purpose. Funds address delays in a fit-out project. They cover larger-than-expected investments. These relate to Inify's UK establishment. The UK market is a key growth area. This funding ensures smooth expansion. It secures future development.
Share settlement follows a timeline. Payment for private placement shares is due around March 25, 2026. New shares will deliver by March 30, 2026. This relies on registration. The Swedish Companies Registration Office must process the capital increase. Euroclear Sweden and Euronext Securities Oslo must also register the shares. Shares will trade on Euronext Growth Oslo. This occurs once all registrations complete.
A repair issue also features in the funding strategy. This issue targets approximately NOK 8 million. It offers new shares. This provides a chance for other investors. It is directed pro-rata. Shareholders not in the private placement can participate. This includes those holding under 1,000,000 shares. The offer price matches the private placement. It is NOK 3.50 per share.
Key dates define the repair issue. Terms were announced on December 17, 2025. The last day to trade with rights was December 16, 2025. The ex-date was December 17, 2025. The record date is December 18, 2025. Shareholders registered in Euronext Securities Oslo (VPS) receive subscription rights. These rights are non-tradable. Euroclear-registered shareholders receive application forms.
The repair issue application period opens in January 2026. It is expected from January 12 to January 26. Final approval for the shares is anticipated around January 27, 2026. A maximum of 2,304,563 new shares are available. This ensures broad shareholder participation. It underscores Inify's commitment to investor fairness.
Inify Laboratories operates at the forefront of diagnostics. The company specializes in histopathology. Its services streamline patient pathways. This includes prostate cancer and gastroenterology diagnostics. Inify provides an integrated service. It spans from sample handling to final diagnosis. Their laboratory system is highly scalable. It handles large patient volumes. It also allows replication in new locations.
Quality is paramount at Inify. Response times are optimized at every step. This covers logistics, tissue preparation, and diagnosis. A fully digital workflow drives this efficiency. It is standardized. It is AI-assisted. This technology sets Inify apart.
Diagnosis remains a human endeavor. Pathologists perform the final diagnosis. Inify’s proprietary AI supports them. This AI boasts world-leading precision. Clinical evaluations confirm its accuracy. The entire workflow operates on a tailor-made system. This system allows for future expansion. It can include additional diagnostic areas.
Inify Laboratories is an international group. Its headquarters are in Stockholm, Sweden. Local laboratories operate in Sweden and the UK. The company’s share trades on Euronext Growth Oslo. Its ticker is INIFY.
The company engaged expert advisors for these transactions. SB1 Markets AS served as financial advisor. Schjødt law firm acted as legal counsel. Their expertise guided Inify through the complex capital raises.
This dual fundraising strategy is crucial. It supports Inify's ambitious growth. It funds essential infrastructure. It expands market reach. The focus on AI-driven diagnostics positions Inify for leadership. It transforms traditional pathology. The company is poised for significant future advancements. It continues to innovate patient care. This ensures long-term financial health. It secures its competitive edge.
The investment reflects market confidence. Investors see value in Inify’s model. Digital pathology is the future. AI integration speeds diagnoses. It boosts accuracy. Inify delivers this future today. Their commitment to innovation remains strong. Their financial foundation is now firmer. This enables continued expansion and technological progress. Inify leads the charge in modern medical diagnostics.